CULLINAN THERAPEUTICS, INC. Operating Lease, Lease Income, Lease Payments
CULLINAN THERAPEUTICS, INC. (CGEM) reported Operating Lease, Lease Income, Lease Payments of $300.00 thousand for the 3-month period ending 2022-12-31, per its 10-Q filed 2022-11-14.
Discontinued › Income Statement › Other Income
us-gaap:OperatingLeaseLeaseIncomeLeasePayments · last filed 2024-03-14
- CULLINAN THERAPEUTICS, INC. operating lease, lease income, lease payments for the quarter ending 2022-12-31 was $300.00K.
- CULLINAN THERAPEUTICS, INC. operating lease, lease income, lease payments for fiscal 2022 was $300.00K.
| Period end | Operating Lease, Lease Income, Lease Payments 3 month | Operating Lease, Lease Income, Lease Payments 12 month |
|---|---|---|
| 2022-12-31 | $300.00K 10-Q · filed 2022-11-14 | $300.00K 10-K · filed 2024-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |